- Home
- LPTX vs SEER Comparison
LPTX vs SEER Comparison
Compare LPTX & SEER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- SEER
- Stock Information
- Founded
- LPTX 2011
- SEER 2017
- Country
- LPTX United States
- SEER United States
- Employees
- LPTX N/A
- SEER N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- SEER Medicinal Chemicals and Botanical Products
- Sector
- LPTX Health Care
- SEER Health Care
- Exchange
- LPTX Nasdaq
- SEER Nasdaq
- Market Cap
- LPTX 119.6M
- SEER 125.3M
- IPO Year
- LPTX N/A
- SEER 2020
- Fundamental
- Price
- LPTX $0.33
- SEER $2.13
- Analyst Decision
- LPTX Hold
- SEER Hold
- Analyst Count
- LPTX 1
- SEER 1
- Target Price
- LPTX N/A
- SEER $3.00
- AVG Volume (30 Days)
- LPTX 3.3M
- SEER 138.6K
- Earning Date
- LPTX 08-11-2025
- SEER 08-07-2025
- Dividend Yield
- LPTX N/A
- SEER N/A
- EPS Growth
- LPTX N/A
- SEER N/A
- EPS
- LPTX N/A
- SEER N/A
- Revenue
- LPTX N/A
- SEER $15,309,000.00
- Revenue This Year
- LPTX N/A
- SEER $26.18
- Revenue Next Year
- LPTX N/A
- SEER $29.58
- P/E Ratio
- LPTX N/A
- SEER N/A
- Revenue Growth
- LPTX N/A
- SEER N/A
- 52 Week Low
- LPTX $0.22
- SEER $1.59
- 52 Week High
- LPTX $4.79
- SEER $2.63
- Technical
- Relative Strength Index (RSI)
- LPTX 48.69
- SEER 51.35
- Support Level
- LPTX $0.28
- SEER $2.13
- Resistance Level
- LPTX $0.36
- SEER $2.23
- Average True Range (ATR)
- LPTX 0.04
- SEER 0.07
- MACD
- LPTX 0.01
- SEER 0.00
- Stochastic Oscillator
- LPTX 39.43
- SEER 53.97
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
About SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.